Impact of the CHA(2)DS(2)-VASc Score on Anticoagulation Recommendations for Atrial Fibrillation.
Am J Med. 2012 Apr 11;
Authors: Mason PK, Lake DE, Dimarco JP, Ferguson JD, Mangrum JM, Bilchick K, Moorman LP, Moorman JR
Abstract
BACKGROUND: The Congestive heart failure, Hypertension, Age?75 years, Diabetes mellitus, Stroke (CHADS(2)) score is used to predict the need for oral anticoagulation for stroke prophylaxis in patients with atrial fibrillation. The Congestive heart failure, Hypertension, Age?75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category (CHA(2)DS(2)-VASc) schema has been proposed as an improvement. Our objective is to determine how adoption of the CHA(2)DS(2)-VASc score alters anticoagulation recommendations. METHODS: Between 2004 and 2008, 1664 patients were seen at the University of Virginia Atrial Fibrillation Center. We calculated the CHADS(2) and CHA(2)DS(2)-VASc scores for each patient. The 2006 American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for atrial fibrillation management were used to determine anticoagulation recommendations based on the CHADS(2) score, and the 2010 European Society of Cardiology guidelines were used to determine anticoagulation recommendations based on the CHA(2)DS(2)-VASc score. RESULTS: The average age was 62±13 years, and 34% were women. Average CHADS(2) and CHA(2)DS(2)-VASc scores were 1.1±1.1 and 1.8±1.5, respectively (P<.0001). The CHADS(2) score classified 33% as requiring oral anticoagulation. The CHA(2)DS(2)-VASc score classified 53% as requiring oral anticoagulation. For women, 31% had a CHADS(2) score?2, but 81% had a CHA(2)DS(2)-VASc score?2 (P.0001). Also, 32% of women with a CHADS(2) score of zero had a CHA(2)DS(2)-VASc score?2. For men, 25% had a CHADS(2) score?2, but 39% had a CHA(2)DS(2)-VASc score?2 (P<.0001). CONCLUSION: Compared with the CHADS(2) score, the CHA(2)DS(2)-VASc score more clearly defines anticoagulation recommendations. Many patients, particularly older women, are redistributed from the low- to high-risk categories.
PMID: 22502952 [PubMed - as supplied by publisher]